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In this issueofBiologyof BloodandMarrowTransplantation,
Bitan et al. [1] present the recommendations of an interna-
tionalworking group of theWorldMarrowDonor Association
(WMDA) relating to the use of children as stem cell donors.
They describe issues regarding medical ethics as related to
this practice, andprovide practical and speciﬁc guidelines and
examples of situations where such donation may not be
appropriate. Hematopoietic stem cell transplantation (HSCT)
hasnowbeenperformed formore than50years [2]. Theuseof
children as stem cell donors for sick siblings has increased as
the indications forHSCThaveexpanded. Theuseof children in
this setting bringswith it a complex set of considerations, the
majority of which are ethical in nature.
First and foremost among these ethical considerations is
the issue of consent. The Nuremberg Code sets a high bar for
consent: “The voluntary consent of the human subject is
absolutely essential. This means that the person involved
should have legal capacity to give consent” [3]. By deﬁnition,
then, theNurembergCodedoesnot recognize that childrencan
give consent. TheDeclarationofHelsinki allows for inclusionof
children through the following statement: “When a potential
research subject who is deemed incapable of giving informed
consent is able togiveassent todecisionsaboutparticipation in
research, the physicianmust seek that assent in addition to the
consent of the legally authorized representative” [4]. However
even in the Declaration of Helsinki there are caveats related to
the fact that the donor is assuming some risk without the
potential for beneﬁt [4]. It is important to note that both the
Nuremberg Code and the Declaration of Helsinki werewritten
to describe consent/assent in the research context, and there
aremany situationswhere neither the donor nor the recipient
will be a research subject in the HSCT ﬁeld.
Bitan et al. present an eloquent summary of the issues
surrounding the ability of the donor to understand the pro-
cedures, the conﬂict of parents as they assess the risk to the
donor compared with the potential beneﬁt to the recipient,
and the true voluntariness of the potential donor’s assent in
this context. The authors go on to discuss the concept of
donation in a setting where the donor has an ambivalent or
even negative relationship with the recipient, they ulti-
mately advocate that the key determining factor in this
setting is the need to avoid potential psychological harm to
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donor is a research subject, and address the various
approaches to reviewing and approving such research. Along
the way, they comment on a long-standing and controversial
issue, stating that they do not feel that a donor should be
considered a research subject solely because the recipient is
part of a research study. Finally, they examine an exhaustive
list of clinical conditions that may increase the risk of stem
cell donationwhile not changing the risk for HSCT recipients.
However, they point out that the risk for recipients might
increase when the donor has a genetic disorder, which “is
transmitted” with the HSCT. This would signiﬁcantly change
the risk-beneﬁt assessment of the donorerecipient rela-
tionship, affecting the advisability of sibling donation.
Ultimately, the authors agree with statements from the
American Academy of Pediatrics and the WMDA recom-
mending (1) unbiased health screening and consent by a
health care provider not involved in the care of the recipient
and (2) inclusion of an independent advocate to assess the
relative risks and beneﬁts of the collection [5,6]. In summary,
this is an excellent discussion of the many ethical consider-
ations that surround the use of pediatric sibling HSCT donors,
presenting an important and timely addition to the current
literature on this topic.
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